Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quintiles Opens New Central Lab In Japan
Quintiles said that the new wholly owned facility has expanded testing capabilities with an initial focus on safety testing. The lab started receiving and testing clinical trial samples
Quintiles said that the new wholly owned facility has expanded testing capabilities with an initial focus on safety testing. The lab started receiving and testing clinical trial samples
Both the companies are expected to collaborate on evaluating Tekmira’s stable nucleic acid-lipid particle (SNALP) technology to deliver small interfering RNA (siRNA) molecules provided by Pfizer. Under the
4-Antibody is expected to use its proprietary and unencumbered Hu-PAC and Retrocyte Display technologies for the discovery and development of fully human antibodies against novel targets nominated by
The new capabilities of the Wave RPD System are expected to drive future growth at Celerus beyond IHC and into rapid molecular assays. Feasibility has been demonstrated for
Dako’s HercepTest and HER2 FISH pharmDx enable physicians to identify a group of cancer patients that might benefit from the drug. The CE-marking of Dako’s HercepTest and HER2
Platinum is a pivotal, randomised, controlled clinical trial program designed to support Administration and Japanese Ministry of Health, Labor and Welfare approval of the Promus Element Stent. The
Under the exclusive five-year agreement, Fenwal will market and distribute the ThermoGenesis AXP AutoXpress (AXP) System and BioArchive System for use in cord blood processing and storage in
Benson Group said that through Advanced Planning and Scheduling, it has been able to achieve a much higher utilisation of its manufacturing lines, reduced downtime between jobs and
Chesapeake said that the choice of press, following exhaustive trials at Komori’s Graphic Technology Centres in Japan and Holland, will be installed in June. The press has been
Risedronate sodium hydrate is a bisphosphonate antiosteoporotic agent, which is currently approved in more than 90 countries. A once-monthly formulation of risedronate sodium hydrate was already approved outside